Side effects and safety of medicinal cannabis

Updated 14 June 2019
Temabillede om medicinsk cannabis med tekst

The products that are included in the medicinal cannabis pilot programme have not been studied in the same systematic way as the method used for authorised medicines. This means, among other things, that the scientific evidence of side effects is very limited.

It is very important that doctors and patients report all suspected side effects of medicinal cannabis to the Danish Medicines Agency so we can learn more about how the different products affect the body.

What we know about side effects of THC and CBD

The knowledge that the Danish Medicines Agency currently has about side effects of medicinal cannabis is primarily based on international clinical studies of cannabis-based medicines such as Sativex, Cesamet/Nabilone and Marinol.

Some of the side effects of THC-containing products are: sleepiness, dizziness, mood changes, anxiety, concentration and memory problems, low blood pressure causing fainting, and effects on the ability to drive. Among the more serious psychiatric symptoms are depression, hallucinations, paranoia, delusions and suicidal thoughts. If you use THC-containing products for longer periods, you are at risk of developing dependence. This has been seen when patients with chronic pain are treated with medicinal cannabis. When it comes to long term use, the knowledge of side effects is generally limited, but it cannot be ruled out that concentration and learning ability are negatively affected.

There is only very limited knowledge about the side effects caused by CBD. There is evidence that CBD may affect the liver and possibly also the immune system.

You can find more information about warnings and side effects related to medicinal cannabis in the guidelines for doctors (in Danish only).

Report all side effects of medicinal cannabis

Doctors are required to report all suspected adverse reactions of cannabis products included in the pilot programme to the Danish Medicines Agency. Patients and relatives (general public) can also report suspected side effects to the Danish Medicines Agency.

We would like to encourage all patients who experience side effects from medicinal cannabis to tell their doctor and to report the side effects to the Danish Medicines Agency. You do not have to be sure that the medicinal cannabis you are taking is causing the symptoms. Only a suspicion is needed for you to report the symptoms as side effects.

To submit a report, please go to the page:

Report a suspected side effect of cannabis end-products – for patients and relatives

We collect side effect reports (sometimes called adverse reaction reports or ADR reports) to find out if there are signals of new or changed risks in relation to the cannabis products of the pilot programme. The ADR reports are part of the basis we use to regularly assess the safety of the products.

You can read ADR overviews for the individual cannabis products below. But before you start using the ADR overviews, it is important that you read the Terms of use of the interactive ADR overviews.

ADR overviews

ADR overviews of products admitted to the Danish Medicines Agency's list of cannabis products covered by the pilot programme (in Danish only):

Bediol "CannGros" (PDF)

Bedrocan "CannGros" (PDF)

CBD Drops "Stenocare" (PDF)

THC Drops "Stenocare" (PDF)

1:1 Drops "Stenocare" (PDF)

Report: Side effects reported for cannabis end-products in 2018 (in Danish only)

Have a question about medicinal cannabis?


If you have a question about cannabis, you are welcome to contact our Information Centre on +45 44 88 95 95 or send an email to dkma@dkma.dk.

You can also post a question on our Facebook page